Therapix Biosciences (NSDQ:TRPX) said today that it inked a sublicense agreement for nasal drug delivery tech from Yissum Research Development Company at the Hebrew University.
According to the deal, Yissum plans to give Therapix an exclusive, global, sub-licensable, royalty-bearing license for its nasal delivery tech to be used with cannabinoids.
Get the full story at our sister site, Drug Delivery Business News.